Van Hulzen Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Van Hulzen Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-319	Closed	-$128K	–	1100
2024 Q4	$128K	Buy	+319	New	+$148K	0.01%	368
2023 Q2	–	Sell	-5,163	Closed	-$1.63M	–	336
2023 Q1	$1.63M	Sell	5,163 -547	-10%	-$164K	0.15%	95
2022 Q4	$1.65M	Sell	5,710 -4	-0.1%	-$1.22K	0.19%	99
2022 Q3	$1.65M	Buy	5,714 +14	+0.2%	+$4.03K	0.2%	94
2022 Q2	$1.61M	Sell	5,700 -71,600	-93%	-$19.2M	0.19%	91
2022 Q1	$20.2M	Buy	77,300 +7,399	+11%	+$1.76M	2.14%	9
2021 Q4	$15.4M	Buy	+69,901	New	+$13.6M	1.68%	15

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Van Hulzen Asset Management's VRTX Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 319 shares — an estimated $128K sold.

Van Hulzen Asset Management first reported a position in VRTX in Q4 2021 and held it in 7 quarters. The position peaked at $20.2M in Q1 2022. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Van Hulzen Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Van Hulzen Asset Management sold 319 Vertex Pharmaceuticals shares in Q1 2025, an estimated $128K.
Van Hulzen Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Van Hulzen Asset Management's Vertex Pharmaceuticals position peaked at $20.2M in Q1 2022.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.